Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is currently recruiting participants for a Phase 2 study titled A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis. The study aims to evaluate the efficacy and safety of targeted therapies for rheumatoid arthritis, a chronic inflammatory disease. This research is significant as it explores new treatment avenues for patients who have not responded to existing therapies.
The study tests three interventions: Lutikizumab monotherapy, Ravagalimab monotherapy, and a combination of both, against placebos. These drugs are administered via subcutaneous injections and aim to reduce symptoms and improve joint function in rheumatoid arthritis patients.
The study employs a randomized, parallel assignment model with double masking to ensure unbiased results. Its primary purpose is treatment-focused, aiming to find effective therapies for rheumatoid arthritis.
The study began on June 20, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on August 19, 2025, indicating ongoing progress.
This study could impact AbbVie’s stock performance positively if successful, as it would enhance their portfolio in the competitive rheumatoid arthritis market. Investors should watch for updates, as positive results could shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.